{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T21:16:39Z","timestamp":1761167799622,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Growth Hormone & IGF Research"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.ghir.2020.02.001","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T14:07:27Z","timestamp":1581430047000},"page":"101312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Changes in plasma amino acids metabolites, caused by long-term IGF-I deficiency, are reversed by IGF-I treatment \u2013 A pilot study"],"prefix":"10.1016","volume":"52","author":[{"given":"Chen","family":"Barazani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haim","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zvi","family":"Laron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"1996","series-title":"Growth Hormone, IGF-I and Growth: New Views of Old Concepts Freund Publishing House, London, UK","author":"Merimee","key":"10.1016\/j.ghir.2020.02.001_bb0005"},{"key":"10.1016\/j.ghir.2020.02.001_bb0010","article-title":"Growth hormone acutely stimulates forearm muscle protein synthesis in normal humans","volume":"260","author":"Fryburg","year":"1991","journal-title":"Am. J. Phys."},{"issue":"3","key":"10.1016\/j.ghir.2020.02.001_bb0015","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1203\/00006450-199603000-00006","article-title":"Growth hormone-binding proteins and insulin-like growth factor-binding proteins in protein-energy malnutrition, before and after nutritional rehabilitation","volume":"39","author":"Zamboni","year":"1996","journal-title":"Pediatr. Res."},{"issue":"1","key":"10.1016\/j.ghir.2020.02.001_bb0020","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/j.2040-4603.2019.tb00062.x","article-title":"Insulin-like growth factor i regulation and its actions in skeletal muscle","volume":"9","author":"Vassilakos","year":"2018","journal-title":"Compr. Physiol."},{"issue":"2","key":"10.1016\/j.ghir.2020.02.001_bb0025","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ecl.2012.04.008","article-title":"Insulin-like growth factor 1 physiology: lessons from mouse models","volume":"41","author":"Yakar","year":"2012","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"10.1016\/j.ghir.2020.02.001_bb0030","first-page":"489","article-title":"Genetic analysis of the pedigrees and molecular defects of the GH-receptor gene in the Israeli cohort of patients with Laron syndrome","author":"Shevah","year":"2006","journal-title":"Pediatr. Endocrinol. Rev. (PER)"},{"key":"10.1016\/j.ghir.2020.02.001_bb0035","first-page":"1031","article-title":"Laron syndrome (primary growth hormone resistance or insensitivity), the personal experience","volume":"2004","author":"Laron","year":"1958","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.ghir.2020.02.001_bb0040","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1210\/jcem-33-2-332","article-title":"Administration of growth hormone to patients with familial dwarfism with high plasma immunoreactive growth hormone: measurement of sulfation factor, metabolic and linear growth responses","volume":"33","author":"Laron","year":"1971","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2020.02.001_bb0045","series-title":"Laron Syndrome \u2013 From Man to Mouse","first-page":"173","article-title":"Lean body mass (LBM) in patients with Laron Syndrome","volume":"19","author":"Laron","year":"2009"},{"key":"10.1016\/j.ghir.2020.02.001_bb0050","series-title":"Muscle-Bone Relationship in Patients with Laron Syndrome","first-page":"171","article-title":"N, Vaisman in Laron Syndrome From Man to Mouse","author":"Epstein","year":"2011"},{"issue":"2","key":"10.1016\/j.ghir.2020.02.001_bb0055","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000185429","article-title":"Muscle force and endurance in untreated and human growth hormone or insulin-like growth factor-I-treated patients with growth hormone deficiency or Laron syndrome","volume":"47","author":"Brat","year":"1997","journal-title":"Horm. Res."},{"issue":"1","key":"10.1016\/j.ghir.2020.02.001_bb0060","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1365-2265.2006.02558.x","article-title":"Body composition in untreated adult patients with Laron syndrome (primary GH insensitivity)","volume":"65","author":"Laron","year":"2006","journal-title":"Clin. Endocrinol."},{"issue":"1","key":"10.1016\/j.ghir.2020.02.001_bb0065","first-page":"19","article-title":"Principles application of liquid chromatography mass spectrometry in clinical biochemistry","volume":"30","author":"James","year":"2009","journal-title":"Clin. Biochem. Rev."},{"key":"10.1016\/j.ghir.2020.02.001_bb0070","first-page":"129","article-title":"The current status of IGF-I assays - a 2009 update","volume":"10","author":"Frystyk","year":"2010","journal-title":"Growth Hormon. IGF Res."},{"issue":"3","key":"10.1016\/j.ghir.2020.02.001_bb0075","first-page":"277","article-title":"If one daily injection of IGF-I has the same growth-promoting effect as 2 injections per day, why continue to give two injections?","volume":"10","author":"Laron","year":"2013","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/j.ghir.2020.02.001_bb0080","series-title":"Laboratory Guide to the Methods in Biochemistry Genetics","first-page":"52","author":"Nenad","year":"2008"},{"year":"2012","series-title":"Pubchem USA: National Center for Biotechnology Information, 16 Sep 2004. Identification Retrieved May","author":"Citrulline \u2013 Compound Summary","key":"10.1016\/j.ghir.2020.02.001_bb0085"},{"issue":"3","key":"10.1016\/j.ghir.2020.02.001_bb0090","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.clnu.2014.04.019","article-title":"Citrulline stimulates muscle protein synthesis in the post-absorptive state in healthy people fed a low-protein diet - A pilot study","volume":"34","author":"Jourdan","year":"2015","journal-title":"Clin. Nutr."},{"issue":"1","key":"10.1016\/j.ghir.2020.02.001_bb0095","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1152\/physrev.1992.72.1.101","article-title":"Physiological actions of taurine","volume":"72","author":"Huxtable","year":"1992","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ghir.2020.02.001_bb0100","first-page":"2673","article-title":"Review: taurine: a \"very essential\" amino acid","volume":"18","author":"Ripps","year":"2012","journal-title":"Mol. Vis."},{"key":"10.1016\/j.ghir.2020.02.001_bb0105","doi-asserted-by":"crossref","first-page":"29389","DOI":"10.1016\/S0021-9258(18)43891-4","article-title":"Inhibition of volume activated I- and taurine efflux from HeLa cells by P-glycoprotein blockers correlates with calmodulin inhibition","volume":"269","author":"Kirk","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.ghir.2020.02.001_bb0110","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4062\/biomolther.2017.251","article-title":"Effects and mechanism of taurine as a therapeutic agent","volume":"26","author":"Schaffer","year":"2018","journal-title":"Biomol. Ther."},{"key":"10.1016\/j.ghir.2020.02.001_bb0115","first-page":"5473","article-title":"Effect of taurine on cell proliferation and apoptosis human lung cancer A549 cells","volume":"15","author":"Tu","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ghir.2020.02.001_bb0120","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1530\/EJE-10-0859","article-title":"Congenital IGF-I deficiency tends to confer protection against post-Natal development of malignancies","volume":"164","author":"Steuerman","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2020.02.001_bb0125","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/nature07762","article-title":"Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression","volume":"457","author":"Sreekumar","year":"2009","journal-title":"Nature."},{"issue":"8","key":"10.1016\/j.ghir.2020.02.001_bb0130","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/recl.19410600805","article-title":"The crystal structure of adipo adipic acid","volume":"60","author":"Mac Gillavry","year":"2010","journal-title":"Recueil des Travaux Chimiques des Pays-Bas"},{"key":"10.1016\/j.ghir.2020.02.001_bb0135","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ymben.2018.07.018","article-title":"Gut microbiota dysbiosis is associated with malnutrition and reduced plasma amino acid levels: lessons from genome-scale metabolic modeling","volume":"49","author":"Kumar","year":"2018","journal-title":"Metab. Eng."},{"key":"10.1016\/j.ghir.2020.02.001_bb0140","doi-asserted-by":"crossref","first-page":"1642S","DOI":"10.1093\/jn\/137.6.1642S","article-title":"Lysine requirement through the human life cycle","volume":"137","author":"Tome","year":"2007","journal-title":"J. Nutr."},{"key":"10.1016\/j.ghir.2020.02.001_bb0145","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ghir.2018.08.002","article-title":"Metabolomics changes in patients with PAPP-A2 deficiency in desponse to rhIGF1 treatment","volume":"42\u201343","author":"Mastrangelo","year":"2018","journal-title":"Growth Hormon. IGF Res."}],"container-title":["Growth Hormone & IGF Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637420300137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637420300137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T22:51:27Z","timestamp":1761087087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096637420300137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":29,"alternative-id":["S1096637420300137"],"URL":"https:\/\/doi.org\/10.1016\/j.ghir.2020.02.001","relation":{},"ISSN":["1096-6374"],"issn-type":[{"type":"print","value":"1096-6374"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in plasma amino acids metabolites, caused by long-term IGF-I deficiency, are reversed by IGF-I treatment \u2013 A pilot study","name":"articletitle","label":"Article Title"},{"value":"Growth Hormone & IGF Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ghir.2020.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101312"}}